The HPA Axis and Peptide Modulation: Stress Response Research

# The HPA Axis and Peptide Modulation: Stress Response Research

For Research Purposes Only — Not Intended for Human or Animal Consumption

Introduction

The hypothalamic-pituitary-adrenal (HPA) axis is the primary neuroendocrine stress response system. It coordinates the body's response to physical and psychological stressors through a cascade of hormonal signals culminating in cortisol release from the adrenal cortex. Multiple research peptides interact with the HPA axis — some as unintended side effects (GHRPs), others as potential therapeutic targets (BPC-157, Selank).

HPA Axis Physiology

The HPA axis operates through a hierarchical cascade:

Hypothalamus → CRH: In response to stress signals, the hypothalamic paraventricular nucleus (PVN) releases corticotropin-releasing hormone (CRH) into the hypothalamo-pituitary portal circulation.

Pituitary → ACTH: CRH stimulates corticotroph cells in the anterior pituitary to release adrenocorticotropic hormone (ACTH) into systemic circulation.

Adrenal cortex → Cortisol: ACTH stimulates the adrenal cortex to synthesize and release cortisol (the primary glucocorticoid in humans).

Negative feedback: Cortisol exerts negative feedback at both the hypothalamus and pituitary, inhibiting further CRH and ACTH release. This feedback loop maintains cortisol within a physiological range.

The HPA axis follows a circadian rhythm — cortisol peaks in the early morning (cortisol awakening response) and reaches its nadir in the late evening. Stress superimposes additional cortisol pulses on this baseline rhythm.

GHRPs and HPA Axis Activation

A pharmacologically important property of GH secretagogues (GHRPs) is their ability to activate the HPA axis, producing cortisol elevation as a side effect of GH-releasing activity.

Mechanism: GHS-R1a receptors are expressed not only in pituitary somatotrophs (where they mediate GH release) but also in the hypothalamic PVN and in the pituitary corticotrophs. GHRP activation of these receptors stimulates CRH release from the hypothalamus and ACTH release from the pituitary, leading to cortisol elevation.

Selectivity differences: The degree of HPA axis activation varies significantly among GHRPs: - GHRP-6: Produces significant cortisol elevation (30-60% above baseline) at GH-releasing doses - GHRP-2: Similar cortisol elevation to GHRP-6 - Hexarelin: Significant cortisol elevation - Ipamorelin: Minimal cortisol elevation — the key selectivity advantage that distinguishes it from older GHRPs

The HPA axis activation by non-selective GHRPs is a significant research confound because cortisol has catabolic effects on muscle, impairs immune function, and disrupts sleep — effects that counteract the anabolic goals of GH secretagogue research.

BPC-157 and HPA Axis Modulation

BPC-157 has been studied for effects on the HPA axis in the context of stress-related conditions. Published research suggests that BPC-157 may modulate HPA axis activity:

Corticosterone normalization: In rat models of chronic stress, BPC-157 administration normalized elevated corticosterone (the rodent equivalent of cortisol) levels, suggesting an inhibitory effect on HPA axis hyperactivity.

CRH modulation: Some studies have reported effects of BPC-157 on CRH expression in the hypothalamus, though the direction and magnitude of these effects vary across studies.

The mechanism of BPC-157's HPA axis effects is not fully characterized, but may involve its effects on the gut-brain axis — the vagus nerve and enteric nervous system communicate with the HPA axis, and BPC-157's documented effects on gut function may indirectly modulate HPA axis activity.

Selank and HPA Axis Modulation

Selank's anxiolytic effects are relevant to HPA axis function because anxiety and psychological stress are primary activators of the HPA axis. By reducing anxiety through GABAergic modulation, Selank may indirectly reduce HPA axis activation in stress-exposed research subjects.

Some studies have reported that Selank reduces corticosterone elevation in stressed rats, consistent with its anxiolytic mechanism reducing the psychological stress component of HPA axis activation.

Research Implications

The HPA axis interactions of research peptides have several implications for experimental design:

Cortisol as a confound: In studies using non-selective GHRPs (GHRP-6, GHRP-2, Hexarelin), cortisol elevation is a significant confounding variable for any outcome that is cortisol-sensitive (muscle mass, immune function, sleep, cognitive performance).

Ipamorelin as the preferred GHRP: For most research applications, Ipamorelin's minimal HPA axis activation makes it the preferred GHRP, avoiding cortisol confounds.

Stress model considerations: In stress model research, the HPA axis effects of peptides may be a primary endpoint rather than a confound.

References

1. Raun, K., et al. (1998). Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology, 139(5), 552–561.
2. Sikiric, P., et al. (2019). Stable Gastric Pentadecapeptide BPC 157 as Useful Cytoprotective Peptide Therapy in the Heart Disturbances. Current Pharmaceutical Design, 25(31), 3257–3267.
3. Semenova, T.P., et al. (2010). Selank modulates GABA-A receptor expression in the rat brain. Doklady Biochemistry and Biophysics, 432(1), 127–129.